Skip to main content
. 2013 Jun;14(6):481–489. doi: 10.1016/S1470-2045(13)70096-2

Figure 4.

Figure 4

Progression-free survival in 553 patients in the intention-to-treat population, by treatment group

Patients still on treatment at the time of trial closure and treatment crossover were censored. EOC=epirubicin, oxaliplatin, and capecitabine. mEOC+P=modified EOC plus panitumumab.